AR048722A1 - Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos - Google Patents

Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Info

Publication number
AR048722A1
AR048722A1 ARP050101738A ARP050101738A AR048722A1 AR 048722 A1 AR048722 A1 AR 048722A1 AR P050101738 A ARP050101738 A AR P050101738A AR P050101738 A ARP050101738 A AR P050101738A AR 048722 A1 AR048722 A1 AR 048722A1
Authority
AR
Argentina
Prior art keywords
hormonal
amount
administration
daily
interval
Prior art date
Application number
ARP050101738A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048722(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR048722A1 publication Critical patent/AR048722A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
ARP050101738A 2004-04-30 2005-05-02 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos AR048722A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
AR048722A1 true AR048722A1 (es) 2006-05-17

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101738A AR048722A1 (es) 2004-04-30 2005-05-02 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Country Status (29)

Country Link
US (3) US8163721B2 (cg-RX-API-DMAC7.html)
EP (1) EP1747001B1 (cg-RX-API-DMAC7.html)
JP (4) JP2007535519A (cg-RX-API-DMAC7.html)
KR (4) KR20130022425A (cg-RX-API-DMAC7.html)
CN (1) CN103127156A (cg-RX-API-DMAC7.html)
AR (1) AR048722A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005237255B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510493A (cg-RX-API-DMAC7.html)
CA (1) CA2562296A1 (cg-RX-API-DMAC7.html)
CR (1) CR8709A (cg-RX-API-DMAC7.html)
DK (1) DK1747001T3 (cg-RX-API-DMAC7.html)
EA (2) EA031227B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066999A (cg-RX-API-DMAC7.html)
ES (1) ES2704999T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041475T2 (cg-RX-API-DMAC7.html)
IL (1) IL178458A (cg-RX-API-DMAC7.html)
LT (1) LT1747001T (cg-RX-API-DMAC7.html)
MX (1) MXPA06012567A (cg-RX-API-DMAC7.html)
MY (1) MY151322A (cg-RX-API-DMAC7.html)
NO (1) NO341685B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ586107A (cg-RX-API-DMAC7.html)
PA (1) PA8631801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060467A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201701904TA (cg-RX-API-DMAC7.html)
SI (1) SI1747001T1 (cg-RX-API-DMAC7.html)
SV (1) SV2006002100A (cg-RX-API-DMAC7.html)
TW (1) TWI374735B (cg-RX-API-DMAC7.html)
UY (1) UY28875A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005105103A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
GB2475013A (en) * 2008-09-16 2011-05-04 Playtex Products Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
SMT201800232T1 (it) 2015-06-18 2018-07-17 Mithra Pharmaceuticals S A Unita' di dosaggio orodispersibile contenente un componente di estetrolo
LT3310333T (lt) 2015-06-18 2020-06-25 Estetra Sprl Burnoje dirperguojama vaisto formą, turinti estetrolio komponentą
PT3310345T (pt) 2015-06-18 2021-05-28 Estetra Sprl Comprimido orodispersível contendo estetrol
EP3313408B1 (en) * 2015-06-23 2023-12-06 Laboratorios Leon Farma SA Drospirenone-based contraceptive for a female patient affected with excess weight
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
DK3518933T4 (da) 2016-09-30 2025-04-22 Takeda Pharmaceuticals Co Fremgangsmåder til behandling af uterusfibromer og endometriose
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
CA2261689A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
RS50262B (sr) 1999-08-31 2009-07-15 Bayer Schering Pharma Aktiengesellschaft, Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
EA016625B1 (ru) 2012-06-29
SG10201701904TA (en) 2017-05-30
NO341685B1 (no) 2017-12-18
WO2005105103A2 (en) 2005-11-10
LT1747001T (lt) 2019-01-25
JP2015187157A (ja) 2015-10-29
JP6153967B2 (ja) 2017-06-28
KR20130022425A (ko) 2013-03-06
KR20150058555A (ko) 2015-05-28
EA201200377A8 (ru) 2018-01-31
BRPI0510493A (pt) 2007-11-13
KR20070004919A (ko) 2007-01-09
IL178458A (en) 2016-08-31
CR8709A (es) 2007-08-28
EA031227B1 (ru) 2018-12-28
EA201200377A1 (ru) 2012-08-30
MXPA06012567A (es) 2006-12-15
TW200603781A (en) 2006-02-01
AU2005237255B2 (en) 2011-07-07
PE20060467A1 (es) 2006-06-11
EP1747001A2 (en) 2007-01-31
NO20065499L (no) 2006-11-29
IL178458A0 (en) 2008-04-13
KR20160150113A (ko) 2016-12-28
JP2007535519A (ja) 2007-12-06
US20050250747A1 (en) 2005-11-10
JP2013018787A (ja) 2013-01-31
CA2562296A1 (en) 2005-11-10
UY28875A1 (es) 2005-11-30
US8163721B2 (en) 2012-04-24
WO2005105103A3 (en) 2006-09-08
MY151322A (en) 2014-05-15
JP6134491B2 (ja) 2017-05-24
PA8631801A1 (es) 2006-11-09
HUE041475T2 (hu) 2019-05-28
EA200601908A1 (ru) 2007-04-27
JP2017048253A (ja) 2017-03-09
EP1747001B1 (en) 2018-10-10
AU2005237255A1 (en) 2005-11-10
SV2006002100A (es) 2006-02-15
KR101812160B1 (ko) 2017-12-27
NZ586107A (en) 2012-05-25
SG152288A1 (en) 2009-05-29
DK1747001T3 (en) 2019-02-04
US20150174142A1 (en) 2015-06-25
US20120202779A1 (en) 2012-08-09
TWI374735B (en) 2012-10-21
ES2704999T3 (es) 2019-03-21
SI1747001T1 (sl) 2019-02-28
CN103127156A (zh) 2013-06-05
ECSP066999A (es) 2006-12-29

Similar Documents

Publication Publication Date Title
AR048722A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
PE20051038A1 (es) Uso extendido de combinacion que comprende estrogenos y progestinas
NO20080824L (no) Oral prevensjon med trimegeston
NZ600907A (en) Progestin/estradiol transdermal gel
ES2033850T5 (es) Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Tyler Current status of oral contraception
ES2208518T3 (es) Medio y metodo anticonceptivo hormonal.
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
ECSP056009A (es) Regimenes contraceptivos transdermicos extendidos
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
UY26966A1 (es) Uso de antiprogestinas para la inducción de apoptosis en una célula
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
WO2006042561A2 (en) Intrauterine contraceptive system with copper and progesterone
DE502006000771D1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
CY1112775T1 (el) Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος
Zanartu et al. Progress in human fertility control: the coital use of progestagens
CL2023000450A1 (es) Nueva composición de anticonceptivo oral de liberación modificada
Gruber et al. Satisfaction and compliance of 1333 users of transdermal contraception in private gynaecological practice in Austria
DOP2006000035A (es) Preparación farmaceútica para la anticoncepción oral
CU20060204A7 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
Radzinsky et al. Post-abortion rehabilitation with low-dose combined oral contraceptives: method of optimization of reproductive health
Stika Emergency postcoital contraception
Crist Post-coital estrogen
Sulima et al. Modern methods of contraception

Legal Events

Date Code Title Description
FC Refusal